ArticleNature biotechnology2012
RNA-mediated programmable DNA cleavage.
Article in Nature biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Crops exposed to extreme conditions: perspectives of gene editing to improve stress tolerance.Plant cell reports · 2026Review
- Improving Horticultural Crops via CRISPR/Cas9: Current Successes and Prospects.Plants (Basel, Switzerland) · 2020Review
- Bacterial Genetic Engineering by Means of Recombineering for Reverse Genetics.Frontiers in microbiology · 2020Review
- Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Review
- [Establishment and verification of a mouse model ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
- Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.Molecular medicine reports · 2017Article
- Survival and Evolution of CRISPR-Cas System in Prokaryotes and Its Applications.Frontiers in immunology · 2016Review
- Applications of CRISPR technologies in research and beyond.Nature biotechnology · 2016Article
- Diversity of CRISPR-Cas immune systems and molecular machines.Genome biology · 2015Review
- CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity.Molecular cell · 2014Review
- Targeted genome modification technologies and their applications in crop improvements.Plant cell reports · 2014Review
- Genetically engineered humanized mouse models for preclinical antibody studies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2014Review
- Conditional targeting of Ispd using paired Cas9 nickase and a single DNA template in mice.FEBS open bio · 2014Article
- Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish.Nucleic acids research · 2013Article
- The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.RNA biology · 2013Article
- RNA-guided editing of bacterial genomes using CRISPR-Cas systems.Nature biotechnology · 2013Article
- Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids.PLoS genetics · 2013Article
- Genome-editing tools storm ahead.Nature methods · 2012Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22965054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.